|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These alterations identify a mechanism of genetic instability in malignant B cells and may have been selected during lymphomagenesis for their role in altering BCL6 expression.
|
8618933 |
1995 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 2016 WHO classification defines diffuse large B-cell lymphoma subtypes based on EBV infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers of lymphomagenesis.
|
31123031 |
2020 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because DLCL derive from germinal-center B cells, deregulated BCL-6 expression may contribute to lymphomagenesis by preventing postgerminal center differentiation.
|
7795255 |
1995 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest that BCL6 may function in a 'hit-and-run' role in lymphomagenesis.
|
24887457 |
2014 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dacetuzumab-mediated CD40 signaling constitutively activated the nuclear factor-κB and mitogen-activated protein kinase signaling pathways producing the sustained downregulation of B-cell lymphoma 6 (BCL-6), an oncoprotein implicated in lymphomagenesis.
|
21394099 |
2011 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Translocations and somatic mutations are common genetic alterations of the BCL-6 gene on chromosome 3q27 in B-cell lymphoma, with implications for lymphomagenesis.
|
12775568 |
2003 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
|
16815642 |
2007 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In siRNA experiments, DDX6 appeared not to be involved in NF-κB activation as frequently observed for genes promoting lymphomagenesis but was found to interfere with the expression of BCL6 and BCL2 in an NF-κB independent manner.
|
22965301 |
2013 |
|
Leukemogenesis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant somatic hypermutation and deregulation of the oncogene BCL-6 is associated with lymphomagenesis.
|
17576390 |
2007 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified ID3 mutations in lymphomas with chromosomal aberrations at cMYC and either BCL2 or BCL6 at a frequency intermediate between that of DLBCL and Burkitt lymphoma, hinting at a common pathway in lymphomagenesis for a subset of patients with DHL.
|
24222112 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results provide insight that germline variation in the intergenic region between BCL6 and LPP has a role in risk of B cell lymphomagenesis.
|
23749188 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together these results identify BCL6 as a potential driver of ETV6-RUNX1-mediated leukemogenesis, which could involve loss of BTG1-dependent suppression of ETV6-RUNX1 function.
|
29408281 |
2018 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL6 and miR-155 are implicated in control of GC reaction and lymphomagenesis.
|
30414952 |
2019 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We reveal a molecular mechanism controlling BCL6 stability and propose that mutations and deletions in FBXO11 contribute to lymphomagenesis through BCL6 stabilization.
|
22113614 |
2012 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Repression of AP-1 function by BCL-6 may be a key mechanism for how BCL-6 regulates gene expression to control inflammation, lymphocyte differentiation, and lymphomagenesis.
|
12165517 |
2002 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the significance of deregulated expression of BCL6 in lymphomagenesis and its effect on clinical outcomes of lymphoma patients have remained elusive.
|
12881702 |
2003 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding the precise role of BCL6 in normal GC formation and in lymphomagenesis depends on the identification of genes that are direct targets of its transcriptional repression.
|
12860928 |
2003 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of these mutations, as well as their location in the proximity of BCL-6 regulatory sequences, suggest that they may play a role in AIDS-related lymphomagenesis.
|
9160681 |
1997 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Highlighting the central role of BCL6 in <i>MLL-</i>rearranged B-ALL, conditional deletion and pharmacological inhibition of BCL6 compromised leukemogenesis in transplant recipient mice and restored sensitivity to vincristine chemotherapy in <i>MLL-</i>rearranged B-ALL patient samples.
|
31395741 |
2019 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6.
|
10626250 |
1999 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have shown that the B-cell lymphoma 6 gene (BCL6) is an oncogene that contributes to lymphomagenesis.
|
16264183 |
2005 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these novel data suggest a role for MTA3 in BCL6-mediated lymphomagenesis in germinal centre B cell-like neoplasms.
|
17573669 |
2007 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Constitutive expression of BCL6 mediates lymphomagenesis through aberrant proliferation, survival, and differentiation blockade.
|
17545502 |
2007 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We suggest that expression of BCL-6 in T cells may facilitate lymphomagenesis by repressing critical cytokines and cell cycle regulators.
|
11742039 |
2001 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Promotor substitution leads to deregulation of the BCL6 expression, which may be associated with lymphomagenesis.
|
10953971 |
2000 |